Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells

Leukemia and Lymphoma

Volumn 56, Issue 3, 2015, Pages 730-738

  Ge, Yuqing ^a   Yang, Bo ^a   Xu, Xiaofeng ^b   Dai, Qun ^a   Chen, Zhe ^a   Cheng, Rubin ^a  

^a ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^b Hangzhou Red Cross Hospital   (China)

Author keywords

Bcr Abl pathway; CPT; imatinib resistance; synergism

Indexed keywords

BCR ABL PROTEIN; CRYPTOTANSHINONE; HERBACEOUS AGENT; IMATINIB; INITIATION FACTOR 4E; PHENANTHRENE DERIVATIVE; PROTEIN KINASE INHIBITOR; STAT3 PROTEIN; TARGET OF RAPAMYCIN KINASE;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; K562 CELL LINE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; DRUGS, CHINESE HERBAL; EUKARYOTIC INITIATION FACTOR-4E; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMATINIB MESYLATE; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PHENANTHRENES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAT3 TRANSCRIPTION FACTOR; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 84924670389     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.928934     Document Type: Article

References (26)

1. Druker BJ. Imatinib mesylate in the treatment of chronic myeloid leukaemia. Expert Opin Pharmacother 2003;4:963-971.
2. Gambacorti-Passerini CB, Gunby RH, Piazza R, et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003;4:75-85.
3. Radujkovic A, Schad M, Topaly J, et al. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL - inhibition of P-glycoprotein function by 17-AAG. Leukemia 2005;19:1198-1206.
4. Jung JH, Kwon TR, Jeong SJ, et al. Apoptosis induced by tanshinone IIA and cryptotanshinone is mediated by distinct JAK/STAT3/5 and SHP1/2 signaling in chronic myeloid leukemia K562 cells. Evid Based Complement Alternat Med 2013;2013:805639.
5. Chen W, Liu L, Luo Y, et al. Cryptotanshinone activates p38/JNK and inhibits Erk1/2 leading to caspase-independent cell death in tumor cells. Cancer Prev Res (Phila) 2012;5:778-787.
6. Ge Y, Cheng R, Zhou Y, et al. Cryptotanshinone induces cell cycle arrest and apoptosis of multidrug resistant human chronic myeloid leukemia cells by inhibiting the activity of eukaryotic initiation factor 4E. Mol Cell Biochem 2012;368:17-25.
7. Kong R, Sun B, Jiang H, et al. Downregulation of nuclear factor-kappaB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer. Cancer Lett 2012;291:90-98.
8. Goldman JM, Melo JV. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med 2003;349:1451-1464.
9. Kantarjian HM, Cortes JE, O'Brien S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood 2004;104:1979-1988.
10. Jabbour EJ, Hughes TP, Cortes JE, et al. Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leuk Lymphoma 2013 Nov 12. [Epub head of print]
11. Baran Y, Oztekin C, Bassoy EY. Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myleloid leukemia cells. Cancer Invest 2010;28:623-628.
12. Parekh H, Liu G, Wei M. A new dawn for the use of traditional Chinese medicine in cancer therapy. Mol Cancer 2009;8:21.
13. Gu Y, Chen T, Meng Z, et al. CaMKII gamma, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine. Blood 2012;120:4829-4839.
14. Lee J, Shen P, Zhang G, et al. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib. Biomed Pharmacother 2012;67:157-163.
15. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-880.
16. Wohlbold L, van der Kuip H, Miething C, et al. Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood 2003;102:2236-2239.
17. Ilic N, Utermark T, Widlund HR, et al. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci USA 2011;108:E699-E708.
18. Weisberg E, Manley PW, Cowan-Jacob SW, et al. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007;7:345-356.
19. Santos FP, Ravandi F. Advances in treatment of chronic myelogenous leukemia - new treatment options with tyrosine kinase inhibitors. Leuk Lymphoma 2009;50(Suppl. 2):16-26.
20. Tanaka R, Kimura S. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation. Expert Rev Anticancer Ther 2008;8:1387-1398.
21. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012;367:2075-2088.
22. Topaly J, Zeller WJ, Fruehauf S. Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies. Br J Haematol 2002;119:3-14.
23. Ghez D, Micol JB, Pasquier F, et al. Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis. Eur J Cancer 2014;49:3666-3670.
24. Okabe S, Tauchi T, Tanaka Y, et al. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation. Cancer Biol Ther 2014;15:207-215.
25. Kim JH, Jeong SJ, Kwon TR, et al. Cryptotanshinone enhances TNF-alpha-induced apoptosis in chronic myeloid leukemia KBM-5 cells. Apoptosis 2011;16:696-707.
26. Liu P, Xu S, Zhang M, et al. Anticancer activity in human multiple myeloma U266 cells: synergy between cryptotanshinone and arsenic trioxide. Metallomics 2013;5:871-878.